Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TLC590 in postsurgical pain management
NCT06574269Phase 2Recruiting
- Sponsor
- Taiwan Liposome Company
- Start
- Sep 2024
- Primary completion
- Jul 2026
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
A Phase 2 trial of TLC590 in Persistent postsurgical pain (PPSP), sponsored by Taiwan Liposome Company. Started Sep 2024; status: recruiting.
02
Drugs
TLC590
03
Conditions
Persistent postsurgical pain (PPSP)
Beyond the preview
Go deeper on NCT06574269.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06574269.